戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash).
2 ifesting as nonspecific fever, headache, and maculopapular rash.
3 er, immune suppression, and a characteristic maculopapular rash.
4 tent children is associated with a fever and maculopapular rash.
5 limited clinical symptoms, including diffuse maculopapular rash.
6 ions of eczema and one developed a transient maculopapular rash.
7 and grade 3 pulmonary infection with grade 3 maculopapular rash.
8 e most common were increased lipase (17.8%), maculopapular rash (11.1%), and fatigue (11.1%).
9 d y-glutamyltransferase (20 [15%] patients), maculopapular rash (16 [12%]), and anaemia (15 [11%]); 7
10 ransferase, 17% aspartate aminotransferase), maculopapular rash (17%), and neutropenia (17%).
11 n patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutrope
12 e events of all grades were mucositis (70%), maculopapular rash (51%), and nausea (43%).
13 hatemia (14.0%), neutrophil decrease (9.3%), maculopapular rash (7.0%), and anemia (7.0%).
14 with chemotherapy versus enfortumab vedotin; maculopapular rash (7.4% versus 0%), fatigue (6.8% versu
15 79-related adverse events of all grades were maculopapular rash (76%), mucositis (70%), asthenia (50%
16 of an inclusive case definition (generalized maculopapular rash and fever), and the specificity is in
17 400 mg dose who developed a severe (grade 3) maculopapular rash and terminated treatment.
18 s case was defined as an illness with fever, maculopapular rash, and either cough, coryza or conjunct
19 terised by fever, a generalised erythematous maculopapular rash, and lymphadenopathy.
20 ompanied by clinical symptoms such as fever, maculopapular rash, and/or lymphadenopathy.
21 es included a pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection,
22  elevated amylase (three [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count
23 ion was examined that included a generalized maculopapular rash, fever (>or=38.3 degrees C, if measur
24 ated creatine phosphokinase (five [10%]) and maculopapular rash (five [10%]).
25  in the durvalumab-tremelimumab alone group (maculopapular rash), five (19%) patients in the low-dose
26 ith nine patients under observation (grade 4 maculopapular rash, grade 3 nausea, grade 3 infection, g
27 gue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were
28 eruptions are classically diffuse, symmetric maculopapular rashes involving trunk and extremities.
29 ies, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), an
30 c toxicity consisted of grade 3 erythematous maculopapular rash observed in one patient at 12 mg/m(2)
31 d patients characteristically present with a maculopapular rash, often accompanied by an inoculation
32 s after transplant with fever, diarrhea, and maculopapular rash on her palms, soles, and back.
33                                    Extensive maculopapular rash on the skin was consistent with graft
34 ents were neutropenia (eight [9%] patients), maculopapular rash (seven [8%] patients), and fatigue (s
35 se of varicella was defined as a generalized maculopapular rash that developed in a facility resident